Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales

BALCHEM CORP

2023-FY EPS reported $3.35 revenue$922,439,000

Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.
Full year adjusted EBITDA $230.9M (+7.1%); record free cash flow $151.1M.
Human Nutrition & Health Q4 sales $138M (+5.8%) record; earnings from ops up 43.8%.
Dividend increased double-digit; $25.4M returned to shareholders in 2023.
CEO expects both top and bottom line growth for full year 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

BALCHEM CORP reported Q4 2023 (three months ended December 31, 2023) results: revenue $228.7 million, net income $26.6 million, EPS $0.82.

Period: Q4 2023 (three months ended December 31, 2023)
Revenue: $228.7 million
Net income: $26.6 million
EPS: $0.82
Result: reported results

Exact text from the filing

The Company reported quarterly net sales of $228.7 million, quarterly net earnings of $26.6 million, adjusted EBITDA (a) of $55.4 million, and free cash flow (a) of $56.0 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

BALCHEM CORP reported FY 2023 (year ended December 31, 2023) results: revenue $922.4 million, net income $108.5 million, EPS $3.35.

Period: FY 2023 (year ended December 31, 2023)
Revenue: $922.4 million
Net income: $108.5 million
EPS: $3.35
Result: preliminary results

Exact text from the filing

Full Year 2023 Financial Highlights: • GAAP net earnings were $108.5 million, an increase of 3.0% from the prior year. These net earnings resulted in GAAP earnings per share of $3.35 compared to $3.25 in the prior year.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BALCHEM CORP filing history →

Source: SEC EDGAR

accession 0001628280-24-005203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.